DiscGenics
-
Biologics
DiscGenics Announces Research Collaboration with the U.S. Department of Veterans Affairs for Tissue-Engineered Discs with Discogenic Cells
Feasibility Project Awarded VA Technology Transfer Program BRAVE Funding SALT LAKE CITY, Oct. 18, 2023 /PRNewswire/ — DiscGenics, Inc., a privately held, late-stage…
Read More » -
Spine
DiscGenics Announces Positive Two-Year Clinical Data from Study of Discogenic Progenitor Cell Therapy for Degenerative Disc Disease
Discogenic progenitor cell therapy safely increased disc volume and provided rapid, durable improvements in low back pain, function, quality of…
Read More » -
Spine
DiscGenics to Present at 2022 Cell & Gene Meeting on the Mesa
SALT LAKE CITY, Oct. 5, 2022 /PRNewswire/ — DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Spine
DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and…
Read More » -
Biologics
DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
SALT LAKE CITY and TOKYO, April 27, 2021 /PRNewswire/ — DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Biologics
DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease
SALT LAKE CITY, March 4, 2020 /PRNewswire/ — DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Biologics
DiscGenics’ U.S. Clinical Study of Cell Therapy for Disc Degeneration Passes Halfway Mark
SALT LAKE CITY, Sept. 16, 2019 /PRNewswire/ —DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Spine
DiscGenics Announces First Patients Treated in Japanese Clinical Trial of Cell Therapy for Degenerative Disc Disease
SALT LAKE CITY, Aug. 7, 2019 /PRNewswire/ — DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Biologics
DiscGenics Announces that Cell Therapy IDCT has Passed the Initial Safety Review of its First-in-Human Clinical Trial for Degenerative Disc Disease
SALT LAKE CITY, Jan. 7, 2019 /PRNewswire/ — DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Biologics
DiscGenics Receives Approval from Japanese Pharmaceuticals and Medical Devices Agency to Begin Clinical Evaluation of Non-Surgical Degenerative Disc Disease Treatment in Japan
SALT LAKE CITY, Dec. 11, 2018 /PRNewswire/ — DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate…
Read More » -
Biologics
DiscGenics Announces First Patient Treated in U.S. Clinical Trial of IDCT for Degenerative Disc Disease
SALT LAKE CITY, April 26, 2018 /PRNewswire/ — DiscGenics, Inc., a clinical stage regenerative medicine company focused on developing cell therapies that alleviate…
Read More » -
Financial
DiscGenics Raises $14 Million in Series B Financing
SALT LAKE CITY, Sept. 26, 2017 /PRNewswire/ — DiscGenics, Inc., a clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate…
Read More » -
Hospitals
DiscGenics Fortifies its Intellectual Property Portfolio with 9 Additional Patents
SALT LAKE CITY, Nov. 3, 2016 /PRNewswire/ — DiscGenics, Inc. (DiscGenics) announces the allowance of 9 additional patents that expand its intellectual…
Read More »